



Express Mail No.: EV473971020US
Sheet 1 of 1 of List of References

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10271-063-999

APPLICATION NO.

10/091,313

APPLICANT

Dingivan

FILING DATE

March 4, 2002

ART UNIT

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
/ZS/	A78	2003/0185824	10/02/03	Vaishnav et al.	
/ZS/	A79	2004/0170635	09/02/04	Vaishnav et al.	
/ZS/	A80	2004/0265305	12/30/04	Vaishnav et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
/ZS/	B24	WO 02/060480	08/08/02	Biogen, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
/ZS/	C152	BIMALANGSHU et al., 2005, "Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation," Br. J. Haematol. 128:351-359	
	C153	KOENECKE et al., 2003, "NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507," Exp. Hematol. 31(10):911-23	
	C154	SHAFFER et al., 2005, "Fludarabine treatment is associated with depletion of host CD4+CD25^{HIGH}, FOXP3+, CTLA-4+ cells and increased incidences of full donor chimerism and GVHD in non-myeloablative haploidentical hematopoietic cell transplant recipients," 47th Annual Meeting of the American Society of Hematology, Abstract, 2898	
	C155	SPITZER et al., 2003, "Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies," Transplantation 75(10):1748-51	
	C156	SPITZER et al., 2005, "In vivo and ex vivo T-cell depleted (TCD) nonmyeloablative haploidentical stem cell transplantation (NSCT) for hematologic malignancy (HM)," 47th Annual Meeting of the American Society of Hematology, Abstract, 4731	
	C157	VILLARD et al., 2006, "High percentage of CD4+CD25high expressing FOXP3 and CTLA4 characterized recipient of haploidentical hematopoietic cell transplantation with low T cell recovery," Annual Meeting of the Swiss Society for Allergology and Immunology, Abstract, S33	
	C158	YEE et al., 2005, "Minimal HLA disparity and KIR ligand compatibility in host versus graft direction may facilitate donor engraftment following in vivo and ex vivo T cell depleted (TCD) nonmyeloablative haploidentical stem cell transplantation for hematologic malignancies," 47th Annual Meeting of the American Society of Hematology, Abstract, 3668	

EXAMINER

/Zachary Skelding/

DATE CONSIDERED

06/02/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYI-3949221v1



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10271-063-999

APPLICATION NO.

10/091,313

APPLICANT

Dingivan

FILING DATE

March 4, 2002

ART UNIT

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
/ZS/	A81	2,060,480	11/10/36	Arnold	
	A82	4,980,358	12/25/90	Smith	
	A83	5,587,459	12/24/96	Uckun	
	A84	5,872,223	02/16/99	Uckun	
	A85	5,925,376	07/20/99	Heng	
	A86	6,037,454	03/14/00	Jardieu et al.	
	A87	6,218,410	04/17/01	Uchata et al.	
	A88	6,451,812	09/17/02	End et al.	
	A89	6,582,698	06/24/03	Dedrick et al.	
	A90	2003/0044406	03/06/03	Dingivan	
	A91	2003/0083263	05/01/03	Doronina et al.	
	A92	2004/0127682	07/01/04	Neville et al.	
	A93	60/409,024	09/05/02	Dingivan	
	A94	60/410,385	09/12/02	Dingivan	
	A95	10/091,268	03/04/02	Dingivan	
	A96	10/657,006	09/05/03	Dingivan et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
/ZS/	B25	WO 98/07444	02/26/98	Biotransplant, Inc.		
/ZS/	B26	WO 02/40049	05/23/02	The General Hospital Corporation		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
/ZS/	C159	AU et al., 1996, "Peripheral T-cell lymphoma," Curr. Oncol. Rep. 4(5):434-42	
/ZS/	C160	BERLIN et al., 1992, "Monoclonal antibodies against human T cell adhesion molecules--modulation of immune function in nonhuman primates," Transplantation 53(4):840-849	
/ZS/	C161	CROFFORD and WILDER, 1993, "Arthritis and autoimmunity in animals," in: Arthritis and Allied Conditions:	

EXAMINER

/Zachary Skelding/

DATE CONSIDERED

06/02/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYI-3990242v1



LIST OF REFERENCES SUBMITTED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.
10271-063-999

APPLICATION NO.
10/091,313

APPLICANT
Dingivan

FILING DATE
March 4, 2002

ART UNIT
1644

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		A Textbook of Rheumatology, McCarty et al., eds., Lee & Febiger, Chapter 29	
/ZS/	C162	DEARDEN et al., 2002, "Alemtuzumab in T-cell malignancies," Med. Oncol. 19 Suppl:S27-32	
	C163	DEARDEN et al., 2001, "High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H," Blood 98(6):1721-1726	
	C164	DE LA PARRA, et al., 1991, "Inhibition of T-Cell Activation by Lo-CD2-a, A Rat monoclonal Antibody Against the Human CD2 Glycoprotein," Belgian Journal of Zoology 121(Supp.1):13 Abstract 16	
	C165	DENARDO et al., 1998, "Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts," Clin. Cancer Res. 4(10):2483-2490	
	C166	DENNING et al., 1987, "Monoclonal antibodies to CD2 and lymphocyte function-associated antigen 3 inhibit human thymic epithelial cell-dependent mature thymocyte activation," J. Immunol. 139(8):2573-2578	
	C167	FELDMAN et al., 1998, "Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases," Transplant. Proc. 30(8):4126-7	
	C168	FUJIWARA et al., 2002, "Interferon-alpha therapy following autologous peripheral blood stem cell transplantation for adult T cell leukemia/lymphoma," Acta. Haematol. 107(4):213-219	
	C169	KODAMA et al., 2002, "Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies," Immunol. Lett. 81(2):99-106	
	C170	LIN et al., 1994, "Peripheral T-cell lymphoma in childhood: A report of five cases in Taiwan," Med. And Ped. Oncol. 23:26-35	
	C171	LIN et al., 1996, "Anti-CD2 monoclonal antibody-induced receptor changes. II. Interaction of CD2 and CD3," Cell. Immunol. 167(2):249-58	
	C172	LINDEN et al., 1999, "Psoriasis: Current Perspectives with an Emphasis on Treatment," Am. J. Med. 107(6):595-605	
	C173	MESTAS et al., 2004, "Of mice and not men: differences between mouse and human immunology," J. Immunol. 172(5):2731-8	
	C174	MOHAMMAD et al., 1999, "A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model," Int. J. Oncol. 15(2):367-372	
	C175	NIZET et al., 1999, "Apoptosis of human naive NK cells mediated by a rat IgG2b anti CD2 mAb through a fratricidal ADCC reaction," Immunol. Lett. 68(2-3):229-35	
	C176	PETERSON et al., 1987, "Monoclonal antibody and ligand binding sites of the T cell erythrocyte receptor (CD2)," Nature 329(6142):842-846	
	C177	PHILLIPS et al., 2000, "IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction," Cancer Res. 60(24):6977-6984	
	C178	TAKEMORI et al., 1995, "Significance of PUVA therapy for adult T-cell leukemia/lymphoma - PUVA therapy can induce apoptosis in leukemic cells," Hum. Cell. 8(3):121-126	
	C179	VAN NOORT et al., 1998, "Cell biology of autoimmune diseases," Int. Rev. Cytol. 178:127-206	
	C180	WHITE et al., 1989, "Peripheral T cell lymphoma: value of bone marrow trephine immunophenotyping," J. Clin. Pathol. 42:403-408	
V	C181	WOYKE et al., 2002, "Effect of auristatin PHE on microtubule integrity and nuclear localization in Cryptococcus neoformans," Antimicrob. Agents. Chemother. 46(12):3802-3808	


EXAMINER

/Zachary Skelding/

DATE CONSIDERED

06/02/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10271-063-999

APPLICATION NO.

10/091,313

APPLICANT

Dingivan

FILING DATE

March 4, 2002

ART UNIT

1644

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
/ZS/	C182	WOYKE et al., 2001, "In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE," Antimicrob. Agents Chemother. 45(12):3580-3584	
/ZS/	C183	ZHANG et al., 2003, "Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507," Blood 102(1):284-8	

EXAMINER

/Zachary Skelding/

DATE CONSIDERED

06/02/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYI-3990242v1